Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase
Authors
Keywords
-
Journal
MOLECULES
Volume 24, Issue 18, Pages 3287
Publisher
MDPI AG
Online
2019-09-10
DOI
10.3390/molecules24183287
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Effect of Fluorophore Conjugation on Antibody Affinity and the Photophysical Properties of Dyes
- (2018) Ágnes Szabó et al. BIOPHYSICAL JOURNAL
- GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
- (2018) Aaron D. Springer et al. Nucleic Acid Therapeutics
- Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
- (2017) Fu Li et al. MOLECULAR CANCER THERAPEUTICS
- Overcoming cellular barriers for RNA therapeutics
- (2017) Steven F Dowdy NATURE BIOTECHNOLOGY
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
- (2017) Jayaprakash K. Nair et al. NUCLEIC ACIDS RESEARCH
- Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
- (2015) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- Production of soluble and active microbial transglutaminase inEscherichia colifor site-specific antibody drug conjugation
- (2015) Mathias Rickert et al. PROTEIN SCIENCE
- Versatility of Microbial Transglutaminase
- (2014) Pavel Strop BIOCONJUGATE CHEMISTRY
- Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes
- (2014) Penelope M. Drake et al. BIOCONJUGATE CHEMISTRY
- Mass Spectrometric Characterization of Transglutaminase Based Site-Specific Antibody–Drug Conjugates
- (2013) Santiago E. Farias et al. BIOCONJUGATE CHEMISTRY
- Comparative study of the three different fluorophore antibody conjugation strategies
- (2012) Dilip Shrestha et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Fluorescent-labeled antibodies: Balancing functionality and degree of labeling
- (2010) Shaleen Vira et al. ANALYTICAL BIOCHEMISTRY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- Stability Study of Unmodified siRNA and Relevance to Clinical Use
- (2008) Robyn P. Hickerson et al. OLIGONUCLEOTIDES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started